SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Viking Therapeutics, Inc. (VKTX)

Also .. I have bought my full position

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
zoomlik Member Profile
 
Followed By 2
Posts 386
Boards Moderated 0
Alias Born 10/26/13
160x600 placeholder
Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy ... "PR Newswire (US)" - 10/23/2017 7:05:00 AM
Securities Registration Statement (s-1) "Edgar (US Regulatory)" - 10/17/2017 4:49:11 PM
Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleuko... "PR Newswire (US)" - 10/4/2017 7:05:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/29/2017 4:46:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/29/2017 7:06:35 AM
Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital "PR Newswire (US)" - 9/29/2017 7:05:00 AM
Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settin... "PR Newswire (US)" - 9/25/2017 7:30:00 AM
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatit... "PR Newswire (US)" - 9/11/2017 7:05:00 AM
Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease ... "PR Newswire (US)" - 9/7/2017 7:02:00 AM
Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference "PR Newswire (US)" - 9/5/2017 7:30:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/9/2017 5:04:19 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/9/2017 4:17:47 PM
Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update "PR Newswire (US)" - 8/9/2017 4:05:00 PM
Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017 "PR Newswire (US)" - 8/2/2017 7:30:00 AM
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture "PR Newswire (US)" - 7/12/2017 7:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/6/2017 8:11:19 AM
Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors "PR Newswire (US)" - 7/6/2017 8:00:00 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 6/27/2017 4:31:03 PM
Small Company Offering and Sale of Securities Without Registration (d) "Edgar (US Regulatory)" - 6/22/2017 4:38:53 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/19/2017 4:33:42 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 6/15/2017 5:15:32 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/14/2017 10:02:28 AM
Viking Therapeutics Announces $4.3 Million Registered Direct Offering "PR Newswire (US)" - 6/14/2017 9:55:00 AM
Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) "PR Newswire (US)" - 6/6/2017 7:14:00 AM
Viking Therapeutics to Present at Upcoming Investor Conferences "PR Newswire (US)" - 5/31/2017 7:30:00 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist